• Consensus Rating: Buy
  • Consensus Price Target: $6.00
  • Forecasted Upside: 455.56 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.08
▲ +0.0784 (7.83%)

This chart shows the closing price for NCNA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NuCana Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NCNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NCNA

Analyst Price Target is $6.00
▲ +455.56% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for NuCana in the last 3 months. The average price target is $6.00, with a high forecast of $9.00 and a low forecast of $3.00. The average price target represents a 455.56% upside from the last price of $1.08.

This chart shows the closing price for NCNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in NuCana. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/14/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/13/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/11/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/6/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/22/2022Jefferies Financial GroupLower TargetBuy$21.00 ➝ $3.00Low
4/13/2022Truist FinancialLower Target$22.00 ➝ $6.00High
3/3/2022CowenDowngradeOutperform ➝ Market PerformHigh
11/24/2021HC WainwrightLower TargetBuy$10.00 ➝ $9.00High
3/30/2021William BlairReiterated RatingBuyMedium
1/19/2021HC WainwrightReiterated RatingBuy$10.00Low
12/1/2020HC WainwrightLower TargetBuy$15.00 ➝ $10.00High
11/24/2020HC WainwrightLower TargetBuy$17.00 ➝ $15.00High
10/22/2020Truist FinancialInitiated CoverageBuy$22.00High
9/21/2020OppenheimerReiterated RatingBuy$21.00Medium
8/21/2020Piper SandlerBoost TargetOverweight$15.00 ➝ $17.00High
8/21/2020HC WainwrightBoost TargetBuy$16.00 ➝ $17.00High
8/21/2020OppenheimerReiterated RatingBuy$21.00High
7/29/2020CowenReiterated RatingMarket Perform ➝ AverageLow
7/29/2020Piper SandlerReiterated RatingOverweight$15.00Low
7/23/2020OppenheimerInitiated CoverageOutperform$20.00High
5/19/2020HC WainwrightReiterated RatingBuy$16.00High
5/6/2020HC WainwrightReiterated RatingBuyLow
3/11/2020HC WainwrightLower TargetBuy$17.00 ➝ $16.00High
11/15/2019Piper Jaffray CompaniesLower TargetOverweight$25.00 ➝ $15.00Low
11/15/2019HC WainwrightReiterated RatingBuy$20.00 ➝ $17.00High
10/29/2019HC WainwrightReiterated RatingBuy$20.00High
10/25/2019CowenReiterated RatingBuyLow
9/5/2019William BlairReiterated RatingBuyHigh
8/23/2019Piper Jaffray CompaniesReiterated RatingOverweight$35.00 ➝ $25.00Low
8/21/2019CitigroupSet TargetBuy$25.00Low
8/20/2019Piper Jaffray CompaniesSet TargetBuy$35.00Low
8/19/2019HC WainwrightInitiated CoverageBuy$20.00High
5/16/2019William BlairReiterated RatingOutperformLow
10/18/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$36.00High
8/29/2018CowenReiterated RatingBuyLow
5/24/2018CowenReiterated RatingBuyLow
10/23/2017William BlairInitiated CoverageOutperform ➝ OutperformN/A
10/23/2017CitigroupInitiated CoverageBuy ➝ Buy$23.00N/A
10/23/2017CowenInitiated CoverageOutperformN/A
10/23/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$25.00N/A
(Data available from 10/6/2017 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 9 very negative mentions
3/10/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/9/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/9/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/8/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/8/2022
  • 6 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/7/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/6/2022
  • 1 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
10/6/2022

Current Sentiment

  • 1 very positive mentions
  • 13 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
NuCana logo
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Read More

Today's Range

Now: $1.08
Low: $0.96
High: $1.08

50 Day Range

MA: $1.47
Low: $0.97
High: $1.98

52 Week Range

Now: $1.08
Low: $0.52
High: $3.32

Volume

2,499 shs

Average Volume

116,847 shs

Market Capitalization

$56.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.37

Frequently Asked Questions

What sell-side analysts currently cover shares of NuCana?

The following sell-side analysts have issued reports on NuCana in the last year: Cowen Inc, HC Wainwright, Jefferies Financial Group Inc., and Truist Financial Co..
View the latest analyst ratings for NCNA.

What is the current price target for NuCana?

3 Wall Street analysts have set twelve-month price targets for NuCana in the last year. Their average twelve-month price target is $6.00, suggesting a possible upside of 499.0%. HC Wainwright has the highest price target set, predicting NCNA will reach $9.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $3.00 for NuCana in the next year.
View the latest price targets for NCNA.

What is the current consensus analyst rating for NuCana?

NuCana currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NCNA will outperform the market and that investors should add to their positions of NuCana.
View the latest ratings for NCNA.

What other companies compete with NuCana?

How do I contact NuCana's investor relations team?

NuCana's physical mailing address is 3 Lochside Way, Edinburgh X0, EH12 9DT. The company's listed phone number is 441313571111 and its investor relations email address is [email protected] The official website for NuCana is www.nucana.com. Learn More about contacing NuCana investor relations.